MedPath

Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases

Conditions
Crohn Disease
Colitis, Ulcerative
Registration Number
NCT03841045
Lead Sponsor
Soroka University Medical Center
Brief Summary

Inflammatory Bowel Diseases (IBDs) are a set of recurrent inflammatory conditions that include the colon and small intestine. The two principal conditions include Crohn's disease (CD) and ulcerative colitis (UC). The etiology of which is likely to stem from the interplay of gut microbial imbalances and host. In this study stool cultures, saliva and skin samples will be taken from all participants.

Detailed Description

Recent studies have shown that certain CD patients harbor microbial communities that are distinct from those of healthy individuals. These studies suggest a central role of the gut microbial population in CD. The high complexity of the gut microbiome, which is the most densely populated bacterial niche, makes the identification of these bacteria a significant challenge. The bacterial population is comprised from 1013 - 1014 individuals, all belonging roughly to a thousand different species, mostly anaerobic, and most of them (roughly 70% - 80%) are uncultivable.

The goals of this project are to examine a potential link between bilirubin metabolism and IBD, by comparing fecal extracts from healthy humans and IBD patients, and to investigate the underlying mechanism explaining these differences.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
150
Inclusion Criteria
  • UC
  • CD
  • healthy Volunteers
Exclusion Criteria

• N/A

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
change of bilirubin metabolism in fecal samplesan average of 1 year after recruitment

liquid chromatography / mass spectrometric (LCMS) analysis is applied to bilirubin metabolism comparison between IBD patients and healthy humans in fecal extracts

microbial diversity of fecal matteran average of 1 year after recruitment

16S rRNA sequencing, is used to compare the microbial diversity between healthy individuals and IBD patients

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

soroka MC

🇮🇱

Be'er Sheva, Israel

© Copyright 2025. All Rights Reserved by MedPath